Market Newsdesk

Sanofi selects Jeito Capital as its first investment into a private French-based fund

Paris, France, 13 November 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that Sanofi has made a €50 million investment in Jeito Capital. The investment will be deployed by Jeito’s highly experienced team of pharmaceutical and biotech experts in line with its investment criteria to provide an additional gateway for Sanofi to support French and European healthcare innovation. The coming together of a leader in industry with a leading investor will strengthen the ever-important healthcare eco-system and accelerate access to therapeutic innovation.

Rafaèle Tordjman, Founder and CEO at Jeito, said:
“We are delighted that Sanofi chose to become a major strategic investor in Jeito. Receiving such support from one of the global leaders in healthcare and France’s largest R&D investor underlines Jeito’s commitment to improving healthcare in France and Europe. By bringing together industry and science and providing access to significant capital, Jeito is ideally positioned to deliver on its mission to improve healthcare for patients in France and beyond.”

Paul Hudson, CEO of Sanofi, said:
“We are pleased to collaborate with Jeito Capital and its international team of pharma and biotech experts who are renowned for creating value through innovation. This investment provides Sanofi with access to the very best in French and European healthcare innovation and reinforces our commitment to investing in our medium and long-term development pipeline. We strongly believe in the potential of France and Europe to become a world-class hub for innovation in life sciences, which just needs the appropriate conditions and a stimulating environment in order to thrive.”

Jeito’s unique investment strategy is to provide long-term strategic support to new and established entrepreneurs, primarily in France and Europe, who are aspiring to help patients in need by pioneering novel, groundbreaking medicines that rethink traditional approaches. Leveraging their synergistic experience, Jeito’s team provides continuity from clinical development to market access, especially in Europe and the Unites States, for breakthrough drugs with validated proofs of concept. This continuity is expressed both in the support provided to entrepreneurs by the Jeito team and by the investment of significant capital to ensure the growth of companies, the acceleration towards commercialization and faster access to these major innovations.

This investment is part of Sanofi’s leading contribution to the development of an innovative healthcare eco-system in France and Europe. The company previously collaborated with Bpifrance to launch two public-private investment funds dedicated to French and European life sciences. Sanofi also stands as France’s leading private R&D investor, with more than €2 billion spent locally each year researching new treatments for patients, totaling half of the private research effort in France. Nearly 5,000 researchers and scientists work in a variety of therapeutic areas, mainly focusing on oncology, immuno-oncology, vaccines and rare diseases.

ENDS

About Jeito Capital

Jeito Capital is an international investment company with a patient benefit driven approach that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. Jeito has a unique, long-term investment strategy, with the aim of providing continuity from clinical development to market access for breakthrough drugs with validated proofs of concept. This continuity is expressed both in the support provided to entrepreneurs by the Jeito Capital team and by the investment of significant capital to ensure the growth of companies, the acceleration towards commercialization and faster access to these major innovations.  Jeito Capital is based in Paris with a presence in Europe and the United States.  

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

For more information please contact:

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Company Management will present an update on the Company and its pipeline at the 11^th Annual Jefferies (Virtual) London Healthcare Conference, taking place November 17 – 19, 2020.

ObsEva’s presentation will take place on Wednesday November 18 at 12:55 p.m. Greenwich Mean Time (GMT).  A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, , ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact

Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Attachment

• Press Release in Pdf

Amsterdam, The Netherlands, November 13, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that five abstracts related to its K-NK-cell therapy platform were accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually from December 5-8, 2020.

The ASH abstracts are now available online through the ASH conference website at www.hematology.org/Annual-Meeting/Abstracts/.

Details of the oral presentation are as follows:

• Oral Presentation #68: Haploidentical MbIL-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia
  Presenter: Piyanuch Kongtim, MD
  Affiliation: MD Anderson Cancer Center, Houston, TX
  Session: 704. Immunotherapies: Beyond T to NK
  Presentation Date: Saturday, December 5, 2020: 8:45 AM

Details of the poster presentations are as follows:

• Poster #825: Optimizing Ex-vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined With NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)
  Presenter: Yaya Chu
  Affiliation: New York Medical College, Valhalla, NY
  Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I
  Presentation Date: Saturday, December 5, 2020: 7:00 AM-3:30 PM Poster Hall

• Poster #2151: A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy
  Presenter: Lindsay Rein, MD
  Affiliation: Duke University Medical Center, Durham, NC
  Session: 632. Chronic Myeloid Leukemia: Therapy: Poster II
  Presentation Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster Hall

• Poster #2341: BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
  Presenter: Sumithira Vasu, MD
  Affiliation: The Ohio State University, Columbus, OH
  Session: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster II
  Presentation Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster Hall

• Poster #2347: A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
  Presenter: Sumithira Vasu
  Affiliation: The Ohio State University, Columbus, OH
  Session: 704. Immunotherapies: Poster II
  Presentation Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster Hall

Dutch Translation/Nederlandse vertaling

Kiadis Pharma N.V.

(“Kiadis”) is een Nederlands beursgenoteerd biotechbedrijf in de klinische fase dat nieuwe geneesmiddelen ontwikkelt tegen ernstige ziekten. Het maakt daarbij gebruik van Natural Killer-cellen (NK-cellen), grote witte bloedlichamen die de eerste verdedigingslinie in het menselijk afweersysteem vormen tegen kankercellen en infecties. Kiadis maakt dat vijf ‘abstracts’ over het K-NK-celtherapieplatform zijn geaccepteerd voor presentatie op de 62e American Society of Hematology (ASH) Annual Meeting and Exposition die virtueel wordt gehouden van 5 tot 8 december 2020.

De ASH-samenvattingen zijn nu online beschikbaar via de ASH-conferentiewebsite op www.hematology.org/Annual-Meeting/Abstracts/.

Details van de presentaties zijn als volgt:

• Poster #2151: Een fase I-onderzoek naar het opnemen van Natural Killer-cellen (K-NK) voor patiënten met chronische myeloïde leukemie (CML) en moleculaire restziekte na therapie met tyrosinekinaseremmers (TKI)
  Presentator: Lindsay Rein, MD
  Gelieerd aan: Duke University Medical Center, Durham, NC
  Sessie: 632. Chronische myeloïde leukemie: therapie: poster II
  Presentatiedatum: zondag 6 december 2020: 7:00 – 15:30 uur, Posterzaal

• Mondelinge presentatie #68: Haplo-identieke MbIL-21 ex vivo geëxpandeerde NK-cellen (FC21-NK) voor patiënten met meervoudige recidiverende en refractaire acute myeloïde leukemie
  Presentator: Piyanuch Kongtim, MD
  Gelieerd aan: MD Anderson Cancer Center, Houston, TX
  Sessie: 704. Immuuntherapie: voorbij T tot NK
  Presentatiedatum: zaterdag 5 december 2020: 8.45 uur

• Poster #825: Optimalisatie van ex-vivo geëxpandeerde NK-celgemedieerde antilichaamafhankelijke cellulaire cytotoxiciteit (ADCC) gecombineerd met NKTR-255 bij chronische lymfatische leukemie (CLL), folliculair lymfoom (FL) en Burkitt lymfoom (BL)
  Presentator: Yaya Chu
  Gelieerd aan: New York Medical College, Valhalla, NY
  Sessie: 203. Lymfocyten, lymfocytactivering en immunodeficiëntie, inclusief hiv en andere infecties: poster I
  Presentatiedatum: zaterdag 5 december 2020: 07:00 – 15:30 uur Posterzaal

• Poster #2341: BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) ter voorkoming van terugval na transplantatie bij AML en MDS (NK-REALM)
  Presentator: Sumithira Vasu, MD
  Gelieerd aan: The Ohio State University, Columbus, OH
  Sessie: 703. Adoptieve immunotherapie: mechanismen en nieuwe benaderingen: poster II
  Presentatiedatum: zondag 6 december 2020: 7:00 – 15:30 uur, Posterzaal

• Poster #2347: Een fase I klinisch onderzoek naar de veiligheid van IL-21-uitgebreide, off-the-shelf natural killer-cellen van derden voor recidiverende/refractaire acute myeloïde leukemie en myelodysplastisch syndroom
  Presentator: Sumithira Vasu
  Gelieerd aan: The Ohio State University, Columbus, OH
  Sessie: 704. Immuuntherapie: Poster II
  Presentatiedatum: zondag 6 december 2020: 7:00 – 15:30 uur, Posterzaal

Dit persbericht vormt een samenvatting van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.

Contacts

About Kiadis

Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

MARSEILLE, France, Nov. 13, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company“) today announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab, the Company’s proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, for the treatment of patients with relapsed or refractory Sézary syndrome (SS) who have received at least two prior systemic therapies.

The PRIME designation is based on efficacy data in relapsed or refractory SS patients from the completed Phase 1 dose escalation and expansion trial, and is supported by safety data in SS patients from both the Phase 1 trial and ongoing Phase 2 TELLOMAK clinical trial. This is the first time PRIME designation has been granted for a potential treatment of any sub-type of T-cell lymphoma.

“
We are pleased that the EMA has granted PRIME designation
for
lacutamab
, as
S
é
zary
syndrome is the most aggressive form of
cutaneous T-cell lymphoma
and
patients facing advanced disease are
in
great
need of new
, targeted
treatment options,” said Joyson Karakunnel, MD, Msc, FACP, Executive Vice President and Chief Medical Officer, Innate Pharma.“Lacutamab is an important asset for our Company,and this designation further validates our work to deliver this potentially first-in-class treatment to patients as quickly as possible.”

PRIME designation by the EMA supports the development of promising new medicines that target an unmet medical need. It allows for proactive support from the EMA throughout the clinical development process and enables accelerated assessment. Lacutumab was also awarded Fast Track designation by the U.S. Food and Drug Administration in 2019 for the treatment of adult patients with relapsed or refractory SS who have received at least two prior systemic therapies. 

About
S
é
zary
Syndrome
:

Sézary syndrome is the leukemic variant of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin’s lymphomas which arise primarily in the skin. Patients often experience very poor quality of life with severe and debilitating pruritus (chronic itchy skin). Despite recent advancements, SS is associated with a high relapse rate with currently available therapies. 

About
Lacutamab
:

Currently in Phase 2 development, lacutamab (IPH4102) is a proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 85% of them with certain aggressive CTCL subtypes, in particular, SS. It has a restricted expression on normal tissues. Lacutamab was granted orphan drug designation in the European Union and in the United States for the treatment of patients with CTCL.

About
the
T
ELLOMAK
Trial:

TELLOMAK is a global, open-label, multi-cohort Phase 2 clinical trial conducted in the United States and Europe. In this clinical trial, lacutamab is being evaluated in patients with advanced t-cell lymphomas (TCL). TELLOMAK is expected to recruit up to 150 patients, with lacutamab evaluated: 

• As a single agent in approximately 60 patients with Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab 
• As a single agent in approximately 90 patients with mycosis fungoides (MF) who have received at least two systemic therapies 

In patients with MF, the study is designed to evaluate the benefit of lacutamab according to KIR3DL2 expression. The study comprises two cohorts in MF, testing lacutamab in KIR3DL2 expressing and non-expressing patients.  These cohorts follow a Simon 2-stage design that will terminate if treatment is considered futile. The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication. 

The primary endpoint of the trial is objective response rate. Key secondary measures include incidence of treatment emergent adverse events, quality of life, overall response rate, progression-free survival and overall survival.  

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the pricing of an underwritten public offering of 17,500,000 shares of its Class A common stock, offered at a price to the public of $3.25 per share. The gross proceeds to Organogenesis Holdings from this offering are expected to be approximately $56.9 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Organogenesis Holdings. Organogenesis Holdings has granted the underwriters a 30-day option to purchase up to an aggregate of 2,625,000 additional shares of its Class A common stock. The offering is expected to close on or about November 17, 2020, subject to customary closing conditions.

Morgan Stanley & Co. LLC and SVB Leerink LLC are acting as joint book-running managers of the offering and BTIG, LLC and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

Organogenesis Holdings intends to use the net proceeds from this offering, together with other available funds, for working capital and general corporate purposes, including, but not limited to, facility expansion and manufacturing enhancements, salesforce expansion and to conduct clinical studies of, obtain regulatory approvals and additional commercial insurance coverage for its products.  The Company will retain broad discretion to allocate the proceeds.

A registration statement on Form S-1 relating to the shares of Class A common stock being offered has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus included in the registration statement declared effective by the SEC, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected], or SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Organogenesis Holdings’ anticipated closing date for the sale of Class A common stock and the use of proceeds from that offering, that involve a number of risks and uncertainties. Statements that are not historical facts are based on Organogenesis Holdings’ current expectations, beliefs and assumptions regarding the market for its Class A common stock. There can be no assurance regarding the completion, timing or size of the proposed offering. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed public offering and others described in Organogenesis Holdings’ registration statement on Form S-1. Organogenesis Holdings cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Organogenesis Holdings undertakes no obligations to update or revise these statements, except as may be required by law.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.